BACKGROUND Globally, prostate cancer is the second most common malignancy in males. Serum microRNAs (miRNAs) may function as non-invasive and innovative biomarkers for various cancers. Our study aimed to determine potential miRNAs for prostate cancer screening. METHODS A three-stage study was accomplished to ascertain crucial miRNAs as markers. In the screening stage, we searched PubMed for aberrantly expressed miRNAs relevant to prostate cancer and selected them as candidate miRNAs. In training and validation stages, with serum specimens from 112 prostate cancer patients and 112 healthy controls, expressions of candidate miRNAs were identified through quantitative reverse transcription-polymerase chain reaction. The diagnostic capabilities of miRNAs were determined by receiver operating characteristic curves. Bioinformatic analysis was utilized to explore the function of the critical miRNAs. RESULTS Expression of six serum miRNAs (miR-34b-3p, miR-556-5p, miR-200c-3p, miR-361-5p, miR-369-3p, miR-485-3p) were significantly altered in prostate cancer patients contrasted with healthy controls. The optimal combination of critical miRNAs is a three-miRNA panel (miR-34b-3p, miR-200c-3p, and miR-361-5p) with good diagnostic capability. FLRT2, KIAA1755, LDB3, and NTRK3 were identified as the potential genes targeted by the three-miRNA panel. CONCLUSIONS The three-miRNA panel may perform as an innovative and promising serum marker for prostate cancer screening.

中文翻译：

---

血清中三微RNA组对于前列腺癌筛查的价值。

背景技术在全球范围内，前列腺癌是男性中第二常见的恶性肿瘤。血清 microRNA (miRNA) 可以作为各种癌症的非侵入性创新生物标志物。我们的研究旨在确定用于前列腺癌筛查的潜在 miRNA。方法 完成了三阶段研究以确定关键的 miRNA 作为标记。在筛选阶段，我们在 PubMed 中搜索与前列腺癌相关的异常表达 miRNA，并选择它们作为候选 miRNA。在训练和验证阶段，利用来自 112 名前列腺癌患者和 112 名健康对照者的血清样本，通过定量逆转录聚合酶链式反应鉴定了候选 miRNA 的表达。miRNA 的诊断能力由受试者工作特征曲线决定。利用生物信息学分析来探索关键 miRNA 的功能。结果前列腺癌患者中六种血清 miRNA（miR-34b-3p、miR-556-5p、miR-200c-3p、miR-361-5p、miR-369-3p、miR-485-3p）的表达显着改变与健康对照相比。关键 miRNA 的最佳组合是具有良好诊断能力的三 miRNA 组合（miR-34b-3p、miR-200c-3p 和 miR-361-5p）。FLRT2、KIAA1755、LDB3 和 NTRK3 被确定为三 miRNA 组的潜在靶基因。结论 三 miRNA 组合可能作为一种创新且有前途的前列腺癌筛查血清标志物。